Howard-CNMC Sickle Cell Disease Clinical Center

霍华德-中色镰状细胞病临床中心

• 批准号: 7405424
• 负责人: Victor R Gordeuk
• 金额: $ 25.2万
• 依托单位: HOWARD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-17 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7405424
• 关键词: Accident and Emergency department; Adolescent; Adult; Age; Arabs; Area; Arts; Blood Pressure; Blood Vessels; Calendar; Caring; Child; Child health care; Classification; Clinic; Clinical; Clinical Protocols; Clinical Trials; Collaborations; Continuity of Patient Care; Development; Diagnosis; District of Columbia; Effectiveness; Elevation; Enrollment; Event; Genotype; Hemoglobin; Hemoglobinopathies; Hydralazine; Institution; Isosorbide Dinitrate; Kidney; Medical center; Multi-Institutional Clinical Trial; Newborn Infant; Numbers; Patients; Population; Preventive Intervention; Protocols documentation; Pulmonary Hypertension; Relative (related person); Research; Research Infrastructure; Safety; Sickle Cell; Sickle Cell Anemia; Testing; United States National Institutes of Health; Universities; Visit; age group; atorvastatin; design; improved; novel therapeutics; prevent; programs; sickling; ward

This is an application to establish a Sickle Cell Disease Clinical Center at Howard University and Childrens National Medical Center in Washington, DC that will also collaborate with the sickle cell disease program at the Clinical Center of the National Institutes of Health in Bethesda, MD. The institutions participating in this Clinical Center follow over 1000 patients with sickle cell disease (SCO) and enroll more than 100 new patients per year. The objectives of the Howard-CNMC Sickle Cell Clinic Center are as follows. Objective 1. To develop the local research infrastructure required for designing and implementing clinical protocols, primarily clinical trials, as part of a multi-center Network of clinics currently treating a large number of sickle cell patients. The Network's main objective is to advance the management of sickle cell disease (SCO) and other hemoglobinopathies by testing the safety, efficacy and effectiveness of new therapeutic and preventive interventions. Objective 2. To propose two multi-center clinical trials as candidate protocols for the Sickle Cell Network. Both trials will focus on lowering sickle cell complications by improving vascular function. The first trial will determine whether atorvastatin administration prevents vaso-occlusive events (crises, ACS). The second study will examine whether the combination of the NO donors, hydralazine and isosorbide dinitrate, prevent the development of pulmonary hypertension and progression of renal/CNS/systemic vasculopathy in SCD patients who have a relative elevation in systemic systolic blood pressure. Objective 3. To help provide comprehensive, state of the art care to children and adults with sickle cell disease (SCD) enrolled in Network clinical protocols. For several decades both, the Howard University Center for Sickle Cell Disease and its proposed collaborating institution, Childrens' National Medical Center (CNMC), have been providing this type of care to a large population of Washington, DC area sickle cell patients. A major feature of both sickle cell programs has always been continuity of care and participation in collaborative research.

这是在霍华德大学和儿童建立镰状细胞疾病临床中心的应用 华盛顿特区的国家医疗中心，该中心还将与镰状细胞疾病计划合作 马里兰州贝塞斯达国立卫生研究院的临床中心。参与此的机构 临床中心遵循1000多名镰状细胞疾病（SCO）患者，并招募了100多名新的 每年患者。 Howard-CNMC镰状细胞诊所中心的目标如下。 目标1。开发设计和实施所需的本地研究基础设施 临床方案，主要是临床试验，是当前诊所网络的一部分 治疗大量的镰状细胞患者。网络的主要目标是促进 通过测试安全性，功效和 新的治疗和预防性干预措施的有效性。 目标2。提出两个多中心临床试验作为镰状细胞的候选方案 网络。这两种试验均应通过改善血管功能来降低镰状细胞并发症。第一个 试验将确定阿托伐他汀给药是否阻止了血管熟悉事件（危机，ACS）。这 第二项研究将检查NO供体，氢化嗪和异氧化物二颗粒酸盐的组合，是否是 防止肺/CNS/全身血管病的肺动脉高压和进展 SCD患者的全身收缩压升高。 目标3。为有助于为儿童和成人提供镰状的儿童和成人的全面，最先进的护理 参加网络临床方案的细胞疾病（SCD）。几十年来，霍华德 大学镰状细胞疾病中心及其提议的合作机构，儿童国家 医疗中心（CNMC）一直为华盛顿特区的大量人口提供此类护理 镰状细胞患者。两个镰状细胞程序的主要特征一直是护理的连续性和 参与协作研究。